3/14/2011 9:16:38 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor. The trial will be conducted at 25 centers throughout the U.S., and Euthymics plans to enroll approximately 300 individuals. Patient recruitment is now underway and top-line results are expected in mid-2012.
comments powered by